253 related articles for article (PubMed ID: 18082233)
1. Antimalarial resistance and DHFR/DHPS genotypes of Plasmodium falciparum three years after introduction of sulfadoxine-pyrimethamine and amodiaquine in rural Tanzania.
Eriksen J; Mwankusye S; Mduma S; Veiga MI; Kitua A; Tomson G; Petzold MG; Swedberg G; Gustafsson LL; Warsame M
Trans R Soc Trop Med Hyg; 2008 Feb; 102(2):137-42. PubMed ID: 18082233
[TBL] [Abstract][Full Text] [Related]
2. Patterns of resistance and DHFR/DHPS genotypes of Plasmodium falciparum in rural Tanzania prior to the adoption of sulfadoxine-pyrimethamine as first-line treatment.
Eriksen J; Mwankusye S; Mduma S; Kitua A; Swedberg G; Tomson G; Gustafsson LL; Warsame M
Trans R Soc Trop Med Hyg; 2004 Jun; 98(6):347-53. PubMed ID: 15099990
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine and the sulfadoxine-pyrimethamine-amodiaquine combination against uncomplicated Plasmodium falciparum malaria in young children in Cameroon.
Basco LK; Same-Ekobo A; Ngane VF; Ndounga M; Metoh T; Ringwald P; Soula G
Bull World Health Organ; 2002; 80(7):538-45. PubMed ID: 12163917
[TBL] [Abstract][Full Text] [Related]
4. Prevention of increasing rates of treatment failure by combining sulfadoxine-pyrimethamine with artesunate or amodiaquine for the sequential treatment of malaria.
Dorsey G; Vlahos J; Kamya MR; Staedke SG; Rosenthal PJ
J Infect Dis; 2003 Oct; 188(8):1231-8. PubMed ID: 14551894
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance.
Mugittu K; Ndejembi M; Malisa A; Lemnge M; Premji Z; Mwita A; Nkya W; Kataraihya J; Abdulla S; Beck HP; Mshinda H
Am J Trop Med Hyg; 2004 Dec; 71(6):696-702. PubMed ID: 15642957
[TBL] [Abstract][Full Text] [Related]
6. Two mutations in dihydrofolate reductase combined with one in the dihydropteroate synthase gene predict sulphadoxine-pyrimethamine parasitological failure in Ugandan children with uncomplicated falciparum malaria.
Talisuna AO; Nalunkuma-Kazibwe A; Langi P; Mutabingwa TK; Watkins WW; Van Marck E; Egwang TG; D'Alessandro U
Infect Genet Evol; 2004 Dec; 4(4):321-7. PubMed ID: 15374529
[TBL] [Abstract][Full Text] [Related]
7. Plasmodium falciparum: evaluation of a quantitative nucleic acid sequence-based amplification assay to predict the outcome of sulfadoxine-pyrimethamine treatment of uncomplicated malaria.
Omar SA; Mens PF; Schoone GJ; Yusuf A; Mwangi J; Kaniaru S; Omer GA; Schallig HD
Exp Parasitol; 2005 May; 110(1):73-9. PubMed ID: 15804381
[TBL] [Abstract][Full Text] [Related]
8. Principal role of dihydropteroate synthase mutations in mediating resistance to sulfadoxine-pyrimethamine in single-drug and combination therapy of uncomplicated malaria in Uganda.
Dorsey G; Dokomajilar C; Kiggundu M; Staedke SG; Kamya MR; Rosenthal PJ
Am J Trop Med Hyg; 2004 Dec; 71(6):758-63. PubMed ID: 15642967
[TBL] [Abstract][Full Text] [Related]
9. Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda.
Staedke SG; Sendagire H; Lamola S; Kamya MR; Dorsey G; Rosenthal PJ
Trop Med Int Health; 2004 May; 9(5):624-9. PubMed ID: 15117308
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of amodiaquine alone and combined with sulfadoxine-pyrimethamine and of sulfadoxine pyrimethamine combined with artesunate.
Rwagacondo CE; Niyitegeka F; Sarushi J; Karema C; Mugisha V; Dujardin JC; Van Overmeir C; van den Ende J; D'Alessandro U
Am J Trop Med Hyg; 2003 Jun; 68(6):743-7. PubMed ID: 12887037
[TBL] [Abstract][Full Text] [Related]
11. Associations of antifolate resistance in vitro and point mutations in dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum.
Biswas S
J Postgrad Med; 2004; 50(1):17-20. PubMed ID: 15047993
[TBL] [Abstract][Full Text] [Related]
12. Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria.
Kyabayinze D; Cattamanchi A; Kamya MR; Rosenthal PJ; Dorsey G
Am J Trop Med Hyg; 2003 Sep; 69(3):247-52. PubMed ID: 14628939
[TBL] [Abstract][Full Text] [Related]
13. Increasing prevalence of wildtypes in the dihydrofolate reductase gene of Plasmodium falciparum in an area with high levels of sulfadoxine/pyrimethamine resistance after introduction of treated bed nets.
Alifrangis M; Lemnge MM; Rønn AM; Segeja MD; Magesa SM; Khalil IF; Bygbjerg IC
Am J Trop Med Hyg; 2003 Sep; 69(3):238-43. PubMed ID: 14628937
[TBL] [Abstract][Full Text] [Related]
14. DHFR and DHPS genotypes of Plasmodium falciparum isolates from Gabon correlate with in vitro activity of pyrimethamine and cycloguanil, but not with sulfadoxine-pyrimethamine treatment efficacy.
Aubouy A; Jafari S; Huart V; Migot-Nabias F; Mayombo J; Durand R; Bakary M; Le Bras J; Deloron P
J Antimicrob Chemother; 2003 Jul; 52(1):43-9. PubMed ID: 12805261
[TBL] [Abstract][Full Text] [Related]
15. Antimalarial efficacy of sulfadoxine-pyrimethamine, amodiaquine and a combination of chloroquine plus sulfadoxine-pyrimethamine in Bundi Bugyo, western Uganda.
Checchi F; Piola P; Kosack C; Ardizzoni E; Klarkowski D; Kwezi E; Priotto G; Balkan S; Bakyaita N; Brockman A; Guthmann JP
Trop Med Int Health; 2004 Apr; 9(4):445-50. PubMed ID: 15078262
[TBL] [Abstract][Full Text] [Related]
16. High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi.
Bwijo B; Kaneko A; Takechi M; Zungu IL; Moriyama Y; Lum JK; Tsukahara T; Mita T; Takahashi N; Bergqvist Y; Björkman A; Kobayakawa T
Acta Trop; 2003 Mar; 85(3):363-73. PubMed ID: 12659974
[TBL] [Abstract][Full Text] [Related]
17. Evidence basis for antimalarial policy change in Sierra Leone: five in vivo efficacy studies of chloroquine, sulphadoxine-pyrimethamine and amodiaquine.
Checchi F; Roddy P; Kamara S; Williams A; Morineau G; Wurie AR; Hora B; Lamotte Nd; Baerwaldt T; Heinzelmann A; Danks A; Pinoges L; Oloo A; Durand R; Ranford-Cartwright L; Smet M;
Trop Med Int Health; 2005 Feb; 10(2):146-53. PubMed ID: 15679557
[TBL] [Abstract][Full Text] [Related]
18. Malaria in the Nuba Mountains of Sudan: baseline genotypic resistance and efficacy of the artesunate plus sulfadoxine-pyrimethamine and artesunate plus amodiaquine combinations.
Hamour S; Melaku Y; Keus K; Wambugu J; Atkin S; Montgomery J; Ford N; Hook C; Checchi F
Trans R Soc Trop Med Hyg; 2005 Jul; 99(7):548-54. PubMed ID: 15869770
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Plasmodium falciparum resistance to sulfadoxine/pyrimethamine in vivo by mutations in the dihydrofolate reductase and dihydropteroate synthetase genes: a comparative study between sites of differing endemicity.
Alifrangis M; Enosse S; Khalil IF; Tarimo DS; Lemnge MM; Thompson R; Bygbjerg IC; Rønn AM
Am J Trop Med Hyg; 2003 Dec; 69(6):601-6. PubMed ID: 14740875
[TBL] [Abstract][Full Text] [Related]
20. Response of falciparum malaria to chloroquine and three second line antimalarial drugs in a Kenyan coastal school age population.
Hagos B; Khan B; Ofulla AV; Kariuki D; Martin SK
East Afr Med J; 1993 Oct; 70(10):620-3. PubMed ID: 8187656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
